Varamir
Desk
News
Calendar
Pricing
Saved
Search
tickers or companies
⌘K
Start free
· no card
Sign in
RACC compared with AMLX: revenue, margins and what each company keeps, and the suppliers and customers both name
RACC
Research Alliance Corp III
Change
Mkt cap
Revenue
Revenue
AMLX
Amylyx Pharmaceuticals, Inc.
Change
Mkt cap
Revenue
Revenue
vs
Compare
RACC
Research Alliance Corp III
vs
AMLX
Amylyx Pharmaceuticals, Inc.
Price
Mkt cap
Revenue
Revenue
Change
Change
Revenue flow
Supply chain
Price
Co-movers
Event sensitivity
Earnings history
Save comparison
Copy link
Earnings history
Desk
News
Calendar
Saved
Search
Earnings history
last 4 reports each · paired by recency
Method
›
RACC
No earnings history for RACC.
AMLX
0 of 4
at or beyond implied
Report
implied
realized
× implied
Q3 FY26
±9.8%
▼
−6.05%
×0.61
Q2 FY26
±25.6%
▲
+10.71%
×0.42
May 7 '26
±11.9%
▼
−5.35%
×0.45
Q1 FY26
±17.6%
▼
−7.78%
×0.44
= implied
RACC realized, solid
AMLX realized, hatched
One scale, both sides: full bar = 26%
× = |realized| ÷ implied
Source: market data
RACC
Research Alliance Corp III
Change
10.14
▼
−0.17%
· post 10.19
Mkt cap
$49.0M
Revenue
—
AMLX
Amylyx Pharmaceuticals, Inc.
Change
29.52
▲
+6.88%
· post 29.09
Closed
Nov 6 '26
Mkt cap
$3.8B
Revenue
$416,000
Q3 FY24
vs
Compare
Closed
Nov 6 '26
RACC
Research Alliance Corp III
vs
AMLX
Amylyx Pharmaceuticals, Inc.
10.14
▼
−0.17%
post 10.19
Price
29.52
▲
+6.88%
post 29.09
$49.0M
Mkt cap
$3.8B
—
Revenue
$416,000
Q3 FY24
Change
Change
RACC
10.14
▼
−0.17%
vs
AMLX
29.52
▲
+6.88%
Closed
Nov 6 '26